Figure 3
Overall survival rates in patients with advanced pancreatic cancer treated by AIT with MUC1-DCs and MUC1-CTLs plus GEM. a; MST was 13.9 months, and the 1-year survival rate was 51.1% in all 42 patients. b; 35 patients who received more than 1 × 107MUC1-DCs per injection (MST, 16.1 months) vs. 7 patients who received less than 1 × 107cells (MST, 6.2 months), p = 0.0036. c; 36 patients who received more than 3 × 108 MUC1-CTLs per injection (MST, 15.1 months) vs. 6 patients who received less than 3 × 108 (MST, 5.2 months), p = 0.0060. d; 30 patients who received both more than 1 × 107MUC1-DCs per injection and 3 × 108 MUC1-CTLs per injection (MST, 16.5 months) vs. the other 12 patients (MST, 5.7 months), p = 0.00020.